UBS Group
NXL icon

UBS Group’s Nexalin Technology NXL Stock Holding History

UBS Group’s Portfolio NXL Stock Details NXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.72K Buy
22,189
+6,288
+40% +$3.27K ﹤0.01% 8558
2025
Q4 		$8.87K Buy
15,901
+15,461
+3,514% +$17.4K ﹤0.01% 8326
2025
Q3 		$403 Sell
440
-14,645
-97% -$13.8K ﹤0.01% 9693
2025
Q2 		$14.9K Buy
+15,085
New +$21.2K ﹤0.01% 8635
2025
Q1 		– Sell
-140
Closed -$386 – 10570
2024
Q4 		$386 Sell
140
-2,326
-94% -$6.47K ﹤0.01% 9493
2024
Q3 		$1.65K Sell
2,466
-1,570
-39% -$1.62K ﹤0.01% 8589
2024
Q2 		$6.82K Sell
4,036
-132
-3% -$194 ﹤0.01% 7885
2024
Q1 		$5.83K Buy
+4,168
New +$1.73K ﹤0.01% 7502
2023
Q3 		– Sell
-2,000
Closed -$1.79K – 9821
2023
Q2 		$1.79K Sell
2,000
-1,158
-37% -$975 ﹤0.01% 7854
2023
Q1 		$2.53K Sell
3,158
-1,243
-28% -$1.23K ﹤0.01% 8495
2022
Q4 		$3.3K Buy
4,401
+258
+6% +$395 ﹤0.01% 9529
2022
Q3 		$4K Buy
+4,143
New +$5.68K ﹤0.01% 9377

Other funds holding NXL

PEAK6
PEAK6 Chicago, Illinois $42.6B AUM 66.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group's NXL Position: Q1 2026 in Review

UBS Group increased its Nexalin Technology (NXL) stake by 40% in Q1 2026, buying an estimated $3.27K and bringing the position to 22,189 shares worth $7.72K. The position accounts for ﹤0.01% of the portfolio, ranked #8558.

UBS Group first reported a position in NXL in Q3 2022 and has held it in 12 quarters since. The position peaked at $14.9K in Q2 2025. 23 funds tracked by Wall St. Rank hold NXL as of Q1 2026.

  • UBS Group held 22,189 shares of Nexalin Technology worth $7.72K as of Q1 2026.
  • UBS Group bought 6,288 Nexalin Technology shares in Q1 2026, an estimated $3.27K.
  • Nexalin Technology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8558 holding.
  • UBS Group first reported a position in Nexalin Technology in Q3 2022 and has held it in 12 quarters since.
  • UBS Group's Nexalin Technology position peaked at $14.9K in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Nexalin Technology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.